cabozantinib,atezolizumab
roche
['bladder', 'cabo ', 'contact-03', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
#kidneybladder oral session starts with #contact-03 phase 3 study of #rcc post ici of atezo+cabo (n=263) vs cabo (n=259) pfs 10.6mo. vs 10.8min hr 1.03 os 25.7mo vs ne hr 0.94 atezo did not improve clinical benefits to cabo post-ici #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own